Cart
sales@molnova.com
Icrucumab
CAS No. 1024603-92-6
Icrucumab( —— )
Catalog No. M36749 CAS No. 1024603-92-6
Icrucumab ( IMC-18F1) is a humanized IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor-1.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 511 | In Stock |
|
| 10MG | 825 | In Stock |
|
| 25MG | 1216 | In Stock |
|
| 50MG | 1609 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIcrucumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionIcrucumab ( IMC-18F1) is a humanized IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor-1.
-
DescriptionIcrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a humanized Anti-VEGFR-1 IgG1 monoclonal antibody. Icrucumab has the potential for the research of advanced solid tumors.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetVEGFR
-
RecptorVEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1024603-92-6
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. LoRusso PM, et al. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. 2014 Apr;32(2):303-11.?
molnova catalog
related products
-
BFH-772
A potent, selective and orally active VEGFR2 tyrosine kinase inhibitor with IC50 of 3 nM.
-
Asimadoline hydrochl...
Asimadoline HCl is a κ-opioid receptor agonist potentially for the treatment of pruritus. Asimadoline has also been shown to be used in the treatment of irritable bowel syndrome.
-
Bucillamine
Bucillamine protects against Ischemia/reperfusion injury in high-risk organ transplants and inhibits the production of VEGF.
